Emerging New Therapeutic Antibody Derivatives for Cancer Treatment

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2022 Feb 8

PMID 35132063

Authors

Shijie Jin

Yanping Sun

Xiao Liang

Xinyu Gu

Jiangtao Ning

Yingchun Xu

Shuqing Chen

Liqiang Pan

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells. The successful application of IgG monoclonal antibodies has inspired the development of various types of therapeutic antibodies, such as antibody fragments, bispecific antibodies, and antibody derivatives (e.g., antibody-drug conjugates and immunocytokines). The miniaturization and multifunctionalization of antibodies are flexible and viable strategies for diagnosing or treating malignant tumors in a complex tumor environment. In this review, we summarize antibodies of various molecular types, antibody applications in cancer therapy, and details of clinical study advances. We also discuss the rationale and mechanism of action of various antibody formats, including antibody-drug conjugates, antibody-oligonucleotide conjugates, bispecific/multispecific antibodies, immunocytokines, antibody fragments, and scaffold proteins. With advances in modern biotechnology, well-designed novel antibodies are finally paving the way for successful treatments of various cancers, including precise tumor immunotherapy, in the clinic.

Citing Articles

Recent Advances in Smart Linkage Strategies for Developing Drug Conjugates for Targeted Delivery.

Zhang J, Yang Z, Liu Y, Liu Y, Qu J, Pan X Top Curr Chem (Cham). 2025; 383(2):13.

PMID: 40080285 DOI: 10.1007/s41061-025-00497-w.

Coding circular RNA in human cancer.

Lin Y, Wang Y, Li L, Zhang K Genes Dis. 2025; 12(3):101347.

PMID: 40034125 PMC: 11875173. DOI: 10.1016/j.gendis.2024.101347.

Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Thway T, Aluri J, Lalovic B, Ooi C, Sauter N, Xing D Clin Transl Sci. 2025; 18(3):e70166.

PMID: 40009571 PMC: 11864228. DOI: 10.1111/cts.70166.

Molecular Chimera in Cancer Drug Discovery: Beyond Antibody Therapy, Designing Grafted Stable Peptides Targeting Cancer.

Chowdhury A, Shrestha P, Jois S Int J Pept Res Ther. 2025; 31(3):38.

PMID: 39974747 PMC: 11832722. DOI: 10.1007/s10989-025-10690-6.

Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response.

Song Y, Teng L, Chen Y, Dong C Chem Bio Eng. 2025; 1(7):633-646.

PMID: 39974696 PMC: 11835264. DOI: 10.1021/cbe.4c00083.

References

Tolmachev V . Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008; 14(28):2999-3019. DOI: 10.2174/138161208786404290. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

Hafeez U, Parakh S, Gan H, Scott A . Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020; 25(20). PMC: 7587605. DOI: 10.3390/molecules25204764. View

Neri D, Sondel P . Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016; 40:96-102. PMC: 5215124. DOI: 10.1016/j.coi.2016.03.006. View

Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-38. PMC: 4023420. DOI: 10.1182/blood-2013-10-535088. View

Halin C, Gafner V, Villani M, Borsi L, Berndt A, Kosmehl H . Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 2003; 63(12):3202-10. View

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

Buss N, Henderson S, McFarlane M, Shenton J, de Haan L . Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012; 12(5):615-22. DOI: 10.1016/j.coph.2012.08.001. View

Shah N, Maatman T, Hari P, Johnson B . Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019; 9:146. PMC: 6423158. DOI: 10.3389/fonc.2019.00146. View

10.

He Q, Jiang X, Zhou X, Weng J . Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019; 12(1):139. PMC: 6921533. DOI: 10.1186/s13045-019-0812-8. View

11.

Hober S, Lindbo S, Nilvebrant J . Bispecific applications of non-immunoglobulin scaffold binders. Methods. 2018; 154:143-152. DOI: 10.1016/j.ymeth.2018.09.010. View

12.

Valedkarimi Z, Nasiri H, Aghebati-Maleki L, Majidi J . Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy. Biomed Pharmacother. 2017; 95:731-742. DOI: 10.1016/j.biopha.2017.07.160. View

13.

Harmsen M, De Haard H . Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007; 77(1):13-22. PMC: 2039825. DOI: 10.1007/s00253-007-1142-2. View

14.

Schlehuber S, Skerra A . Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol Chem. 2001; 382(9):1335-42. DOI: 10.1515/BC.2001.166. View

15.

Huang S, Li F, Liu H, Ye P, Fan X, Yuan X . Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody. MAbs. 2018; 10(6):864-875. PMC: 6152455. DOI: 10.1080/19420862.2018.1486946. View

16.

Hutmacher C, Neri D . Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev. 2018; 141:67-91. DOI: 10.1016/j.addr.2018.09.002. View

17.

Lan Y, Zhang D, Xu C, Hance K, Marelli B, Qi J . Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018; 10(424). DOI: 10.1126/scitranslmed.aan5488. View

18.

Pasqualucci L, Dalla-Favera R . Genetics of diffuse large B-cell lymphoma. Blood. 2018; 131(21):2307-2319. PMC: 5969374. DOI: 10.1182/blood-2017-11-764332. View

19.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

20.

Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki A . Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell. 2011; 147(2):306-19. PMC: 3202669. DOI: 10.1016/j.cell.2011.08.046. View